Literature DB >> 35238957

Longitudinal Observational Study of Cardiac Outcome Risk Factor Prediction in Children, Adolescents, and Adults with Barth Syndrome.

Shahryar Chowdhury1, Lanier Jackson1, Barry J Byrne2, Randall M Bryant3, W Todd Cade4, Tammy Lane Churchill1, Julia Buchanan1, Carolyn Taylor5.   

Abstract

Barth Syndrome (BTHS) is an X-linked mitochondrial cardioskeletal myopathy caused by defects in TAFAZZIN, a gene responsible for cardiolipin remodeling. Altered mitochondrial levels of cardiolipin lead to cardiomyopathy (CM), muscle weakness, exercise intolerance, and mortality. Cardiac risk factors predicting outcome are unknown. Therefore, we conducted a longitudinal observational study to determine risk factors for outcome in BTHS. Subjects with minimum two evaluations (or one followed by death or transplant) were included. Cardiac size, function, and QTc data were measured by echocardiography and electrocardiography at 7 time points from 2002 to 2018. Analysis included baseline, continuous, and categorical variables. Categorical risk factors included prolonged QTc, abnormal right ventricle fractional area change (RV FAC), left ventricle (LV) or RV non-compaction, and restrictive CM phenotype. The association between variables and cardiac death or transplant (CD/TX) was assessed. Median enrollment age was 7 years (range 0.5-22; n = 44). Transplant-free survival (TFS) was 74.4% at 15 years from first evaluation. The cohort demonstrated longitudinal declines in LV size and stroke volume z-scores (end-diastolic volume, p = 0.0002; stroke volume p < 0.0001), worsening RV FAC (p = 0.0405), and global longitudinal strain (GLS) (p = 0.0001) with stable ejection (EF) and shortening (FS) fraction. CD/TX subjects (n = 9) displayed worsening LV dilation (p = 0.0066), EF (p ≤ 0.0001), FS (p = 0.0028), and RV FAC (p = .0032) versus stability in TFS. Having ≥ 2 categorical risk factors predicted CD/TX (p = 0.0073). Over 15 years, 25% of BTHS subjects progressed to CD/TX. Those with progressive LV enlargement, dysfunction, and multiple cardiac risk factors warrant increased surveillance and intense therapy.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Barth syndrome; Heart failure; Mitochondria transplantation; Myopathy; Natural history

Mesh:

Substances:

Year:  2022        PMID: 35238957      PMCID: PMC9462389          DOI: 10.1007/s00246-022-02846-8

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.838


  48 in total

1.  Clinical features and outcomes of childhood dilated cardiomyopathy: results from a national population-based study.

Authors:  Piers E F Daubeney; Alan W Nugent; Patty Chondros; John B Carlin; Steven D Colan; Michael Cheung; Andrew M Davis; C W Chow; Robert G Weintraub
Journal:  Circulation       Date:  2006-11-20       Impact factor: 29.690

2.  Barth syndrome may be due to an acyltransferase deficiency.

Authors:  A F Neuwald
Journal:  Curr Biol       Date:  1997-08-01       Impact factor: 10.834

3.  Characterization of lymphoblast mitochondria from patients with Barth syndrome.

Authors:  Yang Xu; John J Sutachan; Heide Plesken; Richard I Kelley; Michael Schlame
Journal:  Lab Invest       Date:  2005-06       Impact factor: 5.662

4.  Ventricular arrhythmia in the X-linked cardiomyopathy Barth syndrome.

Authors:  C T Spencer; B J Byrne; M H Gewitz; S B Wechsler; A C Kao; E P Gerstenfeld; A D Merliss; M P Carboni; R M Bryant
Journal:  Pediatr Cardiol       Date:  2005 Sep-Oct       Impact factor: 1.655

5.  Deficiency of tetralinoleoyl-cardiolipin in Barth syndrome.

Authors:  Michael Schlame; Jeffrey A Towbin; Paul M Heerdt; Roswitha Jehle; Salvatore DiMauro; Thomas J J Blanck
Journal:  Ann Neurol       Date:  2002-05       Impact factor: 10.422

6.  Natural history of Barth syndrome: a national cohort study of 22 patients.

Authors:  Charlotte Rigaud; Anne-Sophie Lebre; Renaud Touraine; Blandine Beaupain; Chris Ottolenghi; Allel Chabli; Helene Ansquer; Hulya Ozsahin; Sylvie Di Filippo; Pascale De Lonlay; Betina Borm; Francois Rivier; Marie-Catherine Vaillant; Michèle Mathieu-Dramard; Alice Goldenberg; Géraldine Viot; Philippe Charron; Marlene Rio; Damien Bonnet; Jean Donadieu
Journal:  Orphanet J Rare Dis       Date:  2013-05-08       Impact factor: 4.123

Review 7.  Role of Cardiolipin in Mitochondrial Function and Dynamics in Health and Disease: Molecular and Pharmacological Aspects.

Authors:  Giuseppe Paradies; Valeria Paradies; Francesca M Ruggiero; Giuseppe Petrosillo
Journal:  Cells       Date:  2019-07-16       Impact factor: 6.600

8.  Understanding the life experience of Barth syndrome from the perspective of adults: a qualitative one-on-one interview study.

Authors:  Iyar Mazar; Jonathan Stokes; Sarah Ollis; Emily Love; Ashlee Espensen; Peter G Barth; John H Powers; Alan L Shields
Journal:  Orphanet J Rare Dis       Date:  2019-11-07       Impact factor: 4.123

Review 9.  Barth syndrome.

Authors:  Sarah L N Clarke; Ann Bowron; Iris L Gonzalez; Sarah J Groves; Ruth Newbury-Ecob; Nicol Clayton; Robin P Martin; Beverly Tsai-Goodman; Vanessa Garratt; Michael Ashworth; Valerie M Bowen; Katherine R McCurdy; Michaela K Damin; Carolyn T Spencer; Matthew J Toth; Richard I Kelley; Colin G Steward
Journal:  Orphanet J Rare Dis       Date:  2013-02-12       Impact factor: 4.123

10.  Right ventricular involvement in left ventricular non-compaction cardiomyopathy.

Authors:  Simon F Stämpfli; Alexander Gotschy; Pascal Kiarostami; Tardu Özkartal; Christiane Gruner; Markus Niemann; Robert Manka; Felix C Tanner
Journal:  Cardiol J       Date:  2020-07-10       Impact factor: 3.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.